Patents Assigned to QLSF BIOTHERAPEUTICS INC.
  • Humanized anti-PD-L1 antibodies
    Patent number: 11643466
    Abstract: The present disclosure provides isolated binding molecules that bind to and blocks PD-L1, vectors comprising a nucleic acid molecules encoding an amino acid sequence of the binding molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring stimulation of immune responses including cancer.
    Type: Grant
    Filed: August 19, 2021
    Date of Patent: May 9, 2023
    Assignee: QLSF BIOTHERAPEUTICS INC.
    Inventor: Shihao Chen
  • Humanized anti-PD-L1 antibodies
    Patent number: 11124572
    Abstract: The present disclosure provides isolated binding molecules that bind to and blocks PD-L1, vectors comprising a nucleic acid molecules encoding an amino acid sequence of the binding molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring stimulation of immune responses including cancer.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: September 21, 2021
    Assignee: QLSF BIOTHERAPEUTICS INC.
    Inventor: Shihao Chen
  • Antibodies that target human CD47
    Patent number: 10858442
    Abstract: Provided are isolated antibodies that bind to and block CD47, vectors comprising a nucleic acid molecule encoding an amino acid sequence of the binding molecule, and host cells containing the vectors. Methods of making the antibodies, pharmaceutical compositions containing the antibodies, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, such as in treating diseases including cancer, are also provided.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: December 8, 2020
    Assignee: QLSF BIOTHERAPEUTICS INC.
    Inventors: Aaron Kurtzman, Shihao Chen